Fernando Civeira

List of Publications by Year
in descending order

154 papers	6,720 citations	109137 35 h-index	71532 76 g-index
171 all docs	171 docs citations	171 times ranked	6871 citing authors

#	Article	IF	Citations
1	Lipoprotein(a) in hereditary hypercholesterolemia: Influence of the genetic cause, defective gene and type of mutation. Atherosclerosis, 2022, 349, 211-218.	0.4	12
2	Toxic Metals and Subclinical Atherosclerosis in Carotid, Femoral, and Coronary Vascular Territories: The Aragon Workers Health Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 87-99.	1.1	17
3	Effect of the Consumption of Alcohol-Free Beers with Different Carbohydrate Composition on Postprandial Metabolic Response. Nutrients, 2022, 14, 1046.	1.7	3
4	Association of Cholesterol and Oxysterols in Adipose Tissue With Obesity and Metabolic Syndrome Traits. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3929-e3936.	1.8	5
5	Leu22_Leu23 Duplication at the Signal Peptide of PCSK9 Promotes Intracellular Degradation of LDLr and Autosomal Dominant Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 101161ATVBAHA122315499.	1.1	2
6	Triglyceride Metabolism Modifies Lipoprotein(a) Plasma Concentration. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3594-e3602.	1.8	5
7	Diagnostic yield of sequencing familial hypercholesterolemia genes in individuals with primary hypercholesterolemia. Revista Espanola De Cardiologia (English Ed), 2021, 74, 664-673.	0.4	5
8	An alcohol-free beer enriched with isomaltulose and a resistant dextrin modulates gut microbiome in subjects with type 2 diabetes mellitus and overweight or obesity: a pilot study. Food and Function, 2021, 12, 3635-3646.	2.1	19
9	ANGPTL3 gene variants in subjects with familial combined hyperlipidemia. Scientific Reports, 2021, 11, 7002.	1.6	6
10	Maternally inherited hypercholesterolemia does not modify the cardiovascular phenotype in familial hypercholesterolemia. Atherosclerosis, 2021, 320, 47-52.	0.4	7
11	Impact of statin therapy on LDL and non-HDL cholesterol levels in subjects with heterozygous familial hypercholesterolaemia. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1594-1603.	1.1	9
12	SR-B1, a Key Receptor Involved in the Progression of Cardiovascular Disease: A Perspective from Mice and Human Genetic Studies. Biomedicines, 2021, 9, 612.	1.4	20
13	Carga de enfermedad. CÃ¡lculo del riesgo cardiovascular y objetivos terapÃ©uticos. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2021, 33, 10-17.	0.4	0
14	Disbetalipoproteinemia y otras alteraciones relacionadas con la apolipoproteÃna E. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2021, 33, 50-55.	0.4	1
15	EvaluaciÃ³n del coste-efectividad de la utilizaciÃ³n de los inhibidores de PCSK9. Endocrinologia, Diabetes Y NutriciÃ“n, 2021, 68, 369-371.	0.1	4
16	STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway. Journal of Hepatology, 2021, 74, 1429-1441.	1.8	34
17	Cataract Surgery in Elderly Subjects with Heterozygous Familial Hypercholesterolemia in Prolonged Treatment with Statins. Journal of Clinical Medicine, 2021, 10, 3494.	1.0	0
18	Cost-effectiveness evaluation of the use of PCSK9 inhibitors. EndocrinologÃa Diabetes Y NutriciÃ³n (English Ed), 2021, 68, 369-371.	0.1	1

#	Article	IF	Citations
19	MLb-LDLr. JACC Basic To Translational Science, 2021, 6, 815-827.	1.9	10
20	High-protein energy-restricted diets induce greater improvement in glucose homeostasis but not in adipokines comparing to standard-protein diets in early-onset diabetic adults with overweight or obesity. Clinical Nutrition, 2020, 39, 1354-1363.	2.3	10
21	Effect of an alcohol-free beer enriched with isomaltulose and a resistant dextrin on insulin resistance in diabetic patients with overweight or obesity. Clinical Nutrition, 2020, 39, 475-483.	2.3	30
22	Effect of bergamot on lipid profile in humans: A systematic review. Critical Reviews in Food Science and Nutrition, 2020, 60, 3133-3143.	5.4	23
23	Behavioural cardiovascular risk factors and prevalence of diabetes in subjects with familial hypercholesterolaemia. European Journal of Preventive Cardiology, 2020, 27, 1649-1660.	0.8	13
24	Predicted pathogenic mutations in STAP1 are not associated with clinically defined familial hypercholesterolemia. Atherosclerosis, 2020, 292, 143-151.	0.4	21
25	Genetic Confirmation of Monogenic Familial Hypercholesterolemia Advises a More Intensive Lipid-Lowering Approach. JAMA Cardiology, 2020, 5, 1452.	3.0	2
26	Glycerol kinase deficiency in adults: Description of 4 novel cases, systematic review and development of a clinical diagnostic score. Atherosclerosis, 2020, 315, 24-32.	0.4	3
27	High-density lipoprotein characteristics and coronary artery disease: a Mendelian randomization study. Metabolism: Clinical and Experimental, 2020, 112, 154351.	1.5	19
28	Effect of Lifestyle Intervention in the Concentration of Adipoquines and Branched Chain Amino Acids in Subjects with High Risk of Developing Type 2 Diabetes: Feel4Diabetes Study. Cells, 2020, 9, 693.	1.8	7
29	Quantifying Thyroid Hormone Resistance in Obesity. Obesity Surgery, 2020, 30, 2411-2412.	1.1	0
30	Rendimiento diagnÃ³stico de la secuenciaciÃ³n de genes de hipercolesterolemia familiar en sujetos con hipercolesterolemia primaria. Revista Espanola De Cardiologia, 2020, 74, 664-664.	0.6	5
31	Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. New England Journal of Medicine, 2019, 381, 531-542.	13.9	359
32	Genetic predictors of weight loss in overweight and obese subjects. Scientific Reports, 2019, 9, 10770.	1.6	24
33	Indications of PCSK9 inhibitors in clinical practice. Recommendations of the Spanish Society of Arteriosclerosis (SEA), 2019. ClÃnica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2019, 31, 128-139.	0.1	6
34	EstÃ¡ndares SEA 2019 para el control global del riesgo cardiovascular. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2019, 31, 1-43.	0.4	8
35	The Arg499His gain-of-function mutation in the C-terminal domain of PCSK9. Atherosclerosis, 2019, 289, 162-172.	0.4	21
36	Lipid-lowering response in subjects with the p.(Leu167del) mutation in the APOE gene. Atherosclerosis, 2019, 282, 143-147.	0.4	12

#	Article	IF	Citations
37	Indicaciones de los inhibidores de PCSK9 en la prÃ¡ctica clÃnica. Recomendaciones de la Sociedad EspaÃ±ola de Arteriosclerosis (SEA), 2019. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2019, 31, 128-139.	0.4	28
38	Toward a new clinical classification of patients with familial hypercholesterolemia: One perspective from Spain. Atherosclerosis, 2019, 287, 89-92.	0.4	29
39	The island of Gran Canaria: A genetic isolate for familial hypercholesterolemia. Journal of Clinical Lipidology, 2019, 13, 618-626.	0.6	11
40	Effect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia. Atherosclerosis, 2019, 284, 245-252.	0.4	55
41	Lipid Profile Rather Than the LCAT Mutation Explains Renal Disease in Familial LCAT Deficiency. Journal of Clinical Medicine, 2019, 8, 1860.	1.0	10
42	Aortic Valvular Disease in Elderly Subjects with Heterozygous Familial Hypercholesterolemia: Impact of Lipid-Lowering Therapy. Journal of Clinical Medicine, 2019, 8, 2209.	1.0	10
43	Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence. Lipids in Health and Disease, 2019, 18, 216.	1.2	16
44	Impaired Sensitivity to Thyroid Hormones Is Associated With Diabetes and Metabolic Syndrome. Diabetes Care, 2019, 42, 303-310.	4.3	130
45	Clinical and biochemical features of different molecular etiologies of familial chylomicronemia. Journal of Clinical Lipidology, 2018, 12, 920-927.e4.	0.6	97
46	Variantes de un solo nucleÃ³tido asociadas con la hipercolesterolemia poligÃ©nica en familias diagnosticadas de hipercolesterolemia familiar. Revista Espanola De Cardiologia, 2018, 71, 351-356.	0.6	10
47	Different protein composition of low-calorie diet differently impacts adipokine profile irrespective of weight loss in overweight and obese women. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 133-142.	1.1	10
48	Sleep duration and subclinical atherosclerosis: The Aragon Workers' Health Study. Atherosclerosis, 2018, 274, 35-40.	0.4	11
49	Single Nucleotide Variants Associated With Polygenic Hypercholesterolemia in Families Diagnosed Clinically With Familial Hypercholesterolemia. Revista Espanola De Cardiologia (English Ed), 2018, 71, 351-356.	0.4	3
50	Cholesterol oversynthesis markers define familial combined hyperlipidemia versus other genetic hypercholesterolemias independently of body weight. Journal of Nutritional Biochemistry, 2018, 53, 48-57.	1.9	14
51	Hipercolesterolemia familiar en la infancia. El Ã©xito comienza aquÃ. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2018, 30, 179-180.	0.4	0
52	Replacement of cysteine at position 46 in the first cysteine-rich repeat of the LDL receptor impairs apolipoprotein recognition. PLoS ONE, 2018, 13, e0204771.	1.1	2
53	Disappearance of recurrent pancreatitis after splenectomy in familial chylomicronemia syndrome. Atherosclerosis, 2018, 275, 342-345.	0.4	5
54	Efficacy of repeated phlebotomies in hypertriglyceridemia and iron overload: A prospective, randomized, controlled trial. Journal of Clinical Lipidology, 2018, 12, 1190-1198.	0.6	6

#	Article	IF	Citations
55	Association between non-cholesterol sterol concentrations and Achilles tendon thickness in patients with genetic familial hypercholesterolemia. Journal of Translational Medicine, 2018, 16, 6.	1.8	10
56	Familial hypercholesterolaemia in childhood: Success starts here. ClÃnica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2018, 30, 179-180.	0.1	0
57	Energy-restricted, high-protein diets more effectively impact cardiometabolic profile in overweight and obese women than lower-protein diets. Clinical Nutrition, 2017, 36, 371-379.	2.3	24
58	Value of the Definition of Severe Familial Hypercholesterolemia for Stratification of Heterozygous Patients. American Journal of Cardiology, 2017, 119, 742-748.	0.7	17
59	Functional analysis of new 3â€² untranslated regions genetic variants in genes associated with genetic hypercholesterolemias. Journal of Clinical Lipidology, 2017, 11, 532-542.	0.6	9
60	How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?. Atherosclerosis, 2017, 262, 107-112.	0.4	22
61	How to implement clinical guidelines to optimise familial hypercholesterolaemia diagnosis and treatment. Atherosclerosis Supplements, 2017, 26, 25-35.	1.2	20
62	Effect of intensive LDL cholesterol lowering with PCSK9 monoclonal antibodies on tendon xanthoma regression in familial hypercholesterolemia. Atherosclerosis, 2017, 263, 92-96.	0.4	14
63	Tratamiento de la hipercolesterolemia familiar heterocigota en laÂinfancia y laÂadolescencia: unÂproblema noÂresuelto. Revista Espanola De Cardiologia, 2017, 70, 423-424.	0.6	4
64	Association Between the Presence of Carotid Artery Plaque and Cardiovascular Events in Patients With Genetic Hypercholesterolemia. Revista Espanola De Cardiologia (English Ed), 2017, 70, 551-558.	0.4	5
65	Translating the microRNA signature of microvesicles derived from human coronary artery smooth muscle cells in patients with familial hypercholesterolemia and coronary artery disease. Journal of Molecular and Cellular Cardiology, 2017, 106, 55-67.	0.9	45
66	Treatment of Heterozygous Familial Hypercholesterolemia in Children and Adolescents: An Unsolved Problem. Revista Espanola De Cardiologia (English Ed), 2017, 70, 423-424.	0.4	2
67	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. New England Journal of Medicine, 2017, 376, 1527-1539.	13.9	510
68	ABCG5/G8 gene is associated with hypercholesterolemias without mutation in candidate genes and noncholesterol sterols. Journal of Clinical Lipidology, 2017, 11, 1432-1440.e4.	0.6	33
69	The leucine stretch length of PCSK9 signal peptide and its role in development of autosomal dominant hypercholesterolaemia: Unravelling the activities of P.LEU23DEL and P.LEU22_LEU23DUP variants. Atherosclerosis, 2017, 263, e37.	0.4	3
70	Effect of LDL cholesterol, statins and presence of mutations on the prevalence of type 2 diabetes in heterozygous familial hypercholesterolemia. Scientific Reports, 2017, 7, 5596.	1.6	41
71	Bile acid synthesis precursors in subjects with genetic hypercholesterolemia negative for LDLR/APOB/PCSK9/APOE mutations. Association with lipids and carotid atherosclerosis. Journal of Steroid Biochemistry and Molecular Biology, 2017, 169, 226-233.	1.2	6
72	Registro Nacional de Dislipemias de la Sociedad EspaÃ±ola de Arteriosclerosis: situaciÃ³n actual. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2017, 29, 248-253.	0.4	20

#	Article	IF	Citations
73	Rare genetic variants with large effect on triglycerides in subjects with a clinical diagnosis of familial vs nonfamilial hypertriglyceridemia. Journal of Clinical Lipidology, 2016, 10, 790-797.	0.6	13
74	Lipid phenotype and heritage pattern in families with genetic hypercholesterolemia not related to LDLR, APOB, PCSK9, or APOE. Journal of Clinical Lipidology, 2016, 10, 1397-1405.e2.	0.6	12
75	microRNA expression profile in human coronary smooth muscle cell-derived microparticles is a source of biomarkers. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2016, 28, 167-177.	0.4	19
76	Rapid resolution of xanthelasmas after treatment with alirocumab. Journal of Clinical Lipidology, 2016, 10, 1259-1261.	0.6	12
77	Identification and validation of seven new loci showing differential DNA methylation related to serum lipid profile: an epigenome-wide approach. The REGICOR study. Human Molecular Genetics, 2016, 25, 4556-4565.	1.4	77
78	Homozygous Familial Hypercholesterolemia in Spain. Circulation: Cardiovascular Genetics, 2016, 9, 504-510.	5.1	61
79	Frequency of rare mutations and common genetic variations in severe hypertriglyceridemia in the general population of Spain. Lipids in Health and Disease, 2016, 15, 82.	1.2	20
80	Cosegregation of serum cholesterol with cholesterol intestinal absorption markers in families with primary hypercholesterolemia without mutations in LDLR, APOB, PCSK9 and APOE genes. Atherosclerosis, 2016, 246, 202-207.	0.4	15
81	The p.Leu167del Mutation in APOE Gene Causes Autosomal Dominant Hypercholesterolemia by Down-regulation of LDL Receptor Expression in Hepatocytes. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2113-2121.	1.8	71
82	Femoral and Carotid Subclinical Atherosclerosis Association With RiskÂFactors and Coronary Calcium. Journal of the American College of Cardiology, 2016, 67, 1263-1274.	1.2	172
83	IMPROVE-IT clinical implications. Should the â€œhigh-intensity cholesterol-lowering therapyâ€•strategy replace the â€œhigh-intensity statin therapyâ€?. Atherosclerosis, 2015, 240, 161-162.	0.4	64
84	Functional Characterization and Classification of Frequent Low-Density Lipoprotein Receptor Variants. Human Mutation, 2015, 36, 129-141.	1.1	41
85	Prevalence, Vascular Distribution, and Multiterritorial Extent of Subclinical Atherosclerosis in a Middle-Aged Cohort. Circulation, 2015, 131, 2104-2113.	1.6	352
86	Association of Ferritin Elevation and Metabolic Syndrome in Males. Results from the Aragon Workers' Health Study (AWHS). Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2081-2089.	1.8	13
87	Circulating soluble low-density lipoprotein receptor-related protein 1 (sLRP1) concentration is associated with hypercholesterolemia: A new potential biomarker for atherosclerosis. International Journal of Cardiology, 2015, 201, 20-29.	0.8	33
88	ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. European Heart Journal, 2015, 36, ehv370.	1.0	395
89	Serum plant sterols as surrogate markers of dietary compliance inÂfamilial dyslipidemias. Clinical Nutrition, 2015, 34, 490-495.	2.3	1
90	PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2015, 385, 331-340.	6.3	615

#	Article	IF	Citations
91	Monogenic Hypercholesterolemias. Contemporary Endocrinology, 2015, , 177-203.	0.3	0
92	Bile acid synthesis precursors in familial combined hyperlipidemia: The oxysterols 24S-hydroxycholesterol and 27-hydroxycholesterol. Biochemical and Biophysical Research Communications, 2014, 446, 731-735.	1.0	12
93	The human HDL proteome displays high inter-individual variability and is altered dynamically in response to angioplasty-induced atheroma plaque rupture. Journal of Proteomics, 2014, 106, 61-73.	1.2	30
94	Effect of Nicotinic acid/Laropiprant in the lipoprotein(a) concentration with regard to baseline lipoprotein(a) concentration and LPA genotype. Metabolism: Clinical and Experimental, 2014, 63, 365-371.	1.5	15
95	Serum Lipid Responses to Weight Loss Differ between Overweight Adults with Familial Hypercholesterolemia and Those with Familial Combined Hyperlipidemia. Journal of Nutrition, 2014, 144, 1219-1226.	1.3	16
96	Common Genetic Variants Contribute to Primary Hypertriglyceridemia Without Differences Between Familial Combined Hyperlipidemia and Isolated Hypertriglyceridemia. Circulation: Cardiovascular Genetics, 2014, 7, 814-821.	5.1	36
97	Atherosclerosis progression in patients with autosomal dominant hypercholesterolemia in clinical practice. Journal of Clinical Lipidology, 2014, 8, 373-380.	0.6	2
98	A genetic variant in the LDLRpromoter is responsible for part of the LDL-cholesterol variability in primary hypercholesterolemia. BMC Medical Genomics, 2014, 7, 17.	0.7	14
99	Should We Forget About Low-Density Lipoprotein Cholesterol?. Journal of the American College of Cardiology, 2014, 63, 1228-1229.	1.2	18
100	Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia. Circulation, 2014, 129, 234-243.	1.6	204
101	Severe hypercholesterolemia and phytosterolemia with extensive xanthomas in primary biliary cirrhosis: Role of biliary excretion on sterol homeostasis. Journal of Clinical Lipidology, 2014, 8, 520-524.	0.6	12
102	Eicosapentaenoic acid in serum phospholipids relates to a less atherogenic lipoprotein profile in subjects with familial hypercholesterolemia. Journal of Nutritional Biochemistry, 2013, 24, 1604-1608.	1.9	7
103	Simultaneous determination of oxysterols, phytosterols and cholesterol precursors by high performance liquid chromatography tandem mass spectrometry in human serum. Analytical Methods, 2013, 5, 2249.	1.3	44
104	The fine line between familial and polygenic hypercholesterolemia. Clinical Lipidology, 2013, 8, 303-306.	0.4	6
105	Apolipoprotein E gene mutations in subjects with mixed hyperlipidemia and a clinical diagnosis of familial combined hyperlipidemia. Atherosclerosis, 2012, 222, 449-455.	0.4	61
106	Carotid atherosclerosis and lipoprotein particle subclasses in familial hypercholesterolaemia and familial combined hyperlipidaemia. Nutrition, Metabolism and Cardiovascular Diseases, 2012, 22, 591-597.	1.1	35
107	Aragon workersâ€™ health study â€“ design and cohort description. BMC Cardiovascular Disorders, 2012, 12, 45.	0.7	70
108	Age and sex influence the relationship between waist circumference and abdominal fat distribution measured by bioelectrical impedance. Nutrition Research, 2012, 32, 466-469.	1.3	13

#	Article	IF	Citations
109	Omega-3 Fatty Acids and HDL. How Do They Work in the Prevention of Cardiovascular Disease?. Current Vascular Pharmacology, 2012, 10, 432-441.	0.8	34
110	Association of plasma markers of cholesterol homeostasis with metabolic syndrome components. A cross-sectional study. Nutrition, Metabolism and Cardiovascular Diseases, 2011, 21, 651-657.	1.1	24
111	A presumptive new locus for autosomal dominant hypercholesterolemia mapping to 8q24.22. Clinical Genetics, 2011, 79, 475-481.	1.0	25
112	Effect of phlebotomy on lipid metabolism in subjects with hereditary hemochromatosis. Metabolism: Clinical and Experimental, 2011, 60, 830-834.	1.5	19
113	New contributions to the study of common double mutants in the human LDL receptor gene. Die Naturwissenschaften, 2011, 98, 943-949.	0.6	5
114	Functional analysis of LDLR promoter and 5â€² UTR mutations in subjects with clinical diagnosis of familial hypercholesterolemia. Human Mutation, 2011, 32, 868-872.	1.1	26
115	Haplotype analyses, mechanism and evolution of common double mutants in the human LDL receptor gene. Molecular Genetics and Genomics, 2010, 283, 565-574.	1.0	7
116	Iron deposits and dietary patterns in familial combined hyperlipidemia and familial hypertriglyceridemia. Journal of Physiology and Biochemistry, 2010, 66, 229-236.	1.3	5
117	Serum ferritin is a major determinant of lipid phenotype in familial combined hyperlipidemia and familial hypertriglyceridemia. Metabolism: Clinical and Experimental, 2010, 59, 154-158.	1.5	29
118	The genetic basis of familial hypercholesterolemia: inheritance, linkage, and mutations. The Application of Clinical Genetics, 2010, 3, 53.	1.4	49
119	Carotid Intima-Media Thickness in Subjects With No Cardiovascular Risk Factors. Revista Espanola De Cardiologia (English Ed), 2010, 63, 97-102.	0.4	35
120	An NPC1L1 gene promoter variant is associated with autosomal dominant hypercholesterolemia. Nutrition, Metabolism and Cardiovascular Diseases, 2010, 20, 236-242.	1.1	18
121	Higher Incidence of Mild Cognitive Impairment in Familial Hypercholesterolemia. American Journal of Medicine, 2010, 123, 267-274.	0.6	102
122	Impact of low-density lipoprotein receptor mutational class on carotid atherosclerosis in patients with familial hypercholesterolemia. Atherosclerosis, 2010, 208, 437-441.	0.4	43
123	Mutations inHFECausing Hemochromatosis Are Associated with Primary Hypertriglyceridemia. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4391-4397.	1.8	19
124	Overexpression of the CXCL3 gene in response to oxidized low-density lipoprotein is associated with the presence of tendon xanthomas in familial hypercholesterolemia. Biochemistry and Cell Biology, 2009, 87, 493-498.	0.9	10
125	Sonographic evaluation of Achilles tendons and carotid atherosclerosis in familial hypercholesterolemia. Atherosclerosis, 2009, 204, 345-347.	0.4	20
126	Comparison of Genetic Versus Clinical Diagnosis in Familial Hypercholesterolemia. American Journal of Cardiology, 2008, 102, 1187-1193.e1.	0.7	153

#	Article	IF	Citations
127	Frequency of Low-Density Lipoprotein Receptor Gene Mutations in Patients With a Clinical Diagnosis of Familial Combined Hyperlipidemia in a Clinical Setting. Journal of the American College of Cardiology, 2008, 52, 1546-1553.	1.2	73
128	Femoral Atherosclerosis In Heterozygous Familial Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 580-586.	1.1	43
129	Genetic Factors of Cardiovascular Diseases. , 2008, , 44-55.		0
130	Increased Intestinal Cholesterol Absorption in Autosomal Dominant Hypercholesterolemia and No Mutations in the Low-Density Lipoprotein Receptor or Apolipoprotein B Genes. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3667-3673.	1.8	32
131	Hyperlipoproteinaemia(a) is a common cause of autosomal dominant hypercholesterolaemia. Journal of Inherited Metabolic Disease, 2007, 30, 970-977.	1.7	12
132	LipoproteÃnas clÃ¡sicas, terapÃ©uticas modernas. FarmacologÃa de las lipoproteÃnas de alta densidad. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2006, 18, 10-19.	0.4	0
133	Screening of APOB Gene Mutations in Subjects with Clinical Diagnosis of Familial Hypercholesterolemia. Human Biology, 2005, 77, 663-673.	0.4	14
134	The Use of Achilles Tendon Sonography to Distinguish Familial Hypercholesterolemia from Other Genetic Dyslipidemias. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 2203-2208.	1.1	69
135	Tendon Xanthomas in Familial Hypercholesterolemia Are Associated With Cardiovascular Risk Independently of the Low-Density Lipoprotein Receptor Gene Mutation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1960-1965.	1.1	95
136	Tendon xanthomas in familial hypercholesterolemia are associated with a differential inflammatory response of macrophages to oxidized LDL. FEBS Letters, 2005, 579, 4503-4512.	1.3	59
137	Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response. American Heart Journal, 2005, 150, 1154-1162.	1.2	15
138	Screening of APOB gene mutations in subjects with clinical diagnosis of familial hypercholesterolemia. Human Biology, 2005, 77, 663-73.	0.4	2
139	Familial Hypercholesterolemia in Spain: Case-Finding Program, Clinical and Genetic Aspects. Seminars in Vascular Medicine, 2004, 4, 67-74.	2.1	53
140	Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis, 2004, 173, 55-68.	0.4	425
141	Apolipoprotein E genotype is not associated with cardiovascular disease in heterozygous subjects with familial hypercholesterolemia. American Heart Journal, 2003, 145, 999-1005.	1.2	19
142	A common variant in the ABCA1 gene is associated with a lower risk for premature coronary heart disease in familial hypercholesterolaemia. Journal of Medical Genetics, 2003, 40, 163-168.	1.5	83
143	Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis, 2002, 162, 245-251.	0.4	46
144	Analysis of apolipoprotein A-I, lecithin:cholesterol acyltransferase and glucocerebrosidase genes in hypoalphalipoproteinemia. Atherosclerosis, 2002, 163, 49-58.	0.4	19

#	Article	IF	Citations
145	The apolipoprotein B R3500Q gene mutation in Spanish subjects with a clinical diagnosis of familial hypercholesterolemia. Atherosclerosis, 2002, 165, 127-135.	0.4	32
146	A double mutant [N543H+2393del9] allele in the LDL receptor gene in familial hypercholesterolemia: effect on plasma cholesterol levels and cardiovascular disease. Human Mutation, 2002, 20, 477-477.	1.1	9
147	Allelic polymorphism â^'491A/T in apo E gene modulates the lipid-lowering response in combined hyperlipidemia treatment. European Journal of Clinical Investigation, 2002, 32, 421-428.	1.7	24
148	Mutation analysis in 36 unrelated Spanish subjects with familial hypercholesterolemia: Identification of 3 novel mutations in the LDL receptor gene. , 2000, 15, 483-484.		32
149	A Third Major Locus for Autosomal Dominant Hypercholesterolemia Maps to 1p34.1-p32. American Journal of Human Genetics, 1999, 64, 1378-1387.	2.6	154
150	Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia. American Heart Journal, 1999, 138, 156-162.	1.2	26
151	The identification of five novel mutations in the lysosomal acid a-(1,4) glucosidase gene from patients with glycogen storage disease type II. , 1998, 11, 413-413.		25
152	Identification of recurrent and novel mutations in the LDL receptor gene in Spanish patients with familial hypercholesterolemia. Human Mutation, 1998, 11, 413-413.	1.1	29
153	Apo E variants in patients with type III hyperlipoproteinemia. Atherosclerosis, 1996, 127, 273-282.	0.4	46
154	Incomplete dominance of type III hyperlipoproteinemia is associated with the rare apolipoprotein E2 (Arg136 â†' Ser) variant in multigenerational pedigree studies. Atherosclerosis, 1996, 122, 33-46.	0.4	34